Wedbush Equities Analysts Reduce Earnings Estimates for KNSA

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Stock analysts at Wedbush dropped their FY2026 EPS estimates for Kiniksa Pharmaceuticals in a research note issued on Monday, January 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of $1.07 per share for the year, down from their prior estimate of $1.08. Wedbush currently has a "Outperform" rating and a $34.00 price objective on the stock. The consensus estimate for Kiniksa Pharmaceuticals' current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals' FY2027 earnings at $1.44 EPS.

A number of other brokerages also recently issued reports on KNSA. Evercore ISI boosted their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. lifted their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $36.60.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA traded up $0.48 during mid-day trading on Wednesday, reaching $18.82. 552,336 shares of the company were exchanged, compared to its average volume of 515,237. The business has a 50 day simple moving average of $20.94 and a two-hundred day simple moving average of $23.27. The stock has a market capitalization of $1.36 billion, a PE ratio of -134.42 and a beta of 0.29. Kiniksa Pharmaceuticals has a 52 week low of $16.56 and a 52 week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The firm had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals's revenue for the quarter was up 67.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.20) earnings per share.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, CFO Mark Ragosa sold 8,969 shares of the company's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the transaction, the chief financial officer now directly owns 22,958 shares of the company's stock, valued at approximately $492,449.10. This represents a 28.09 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eben Tessari sold 14,000 shares of the firm's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the completion of the sale, the chief operating officer now directly owns 88,975 shares of the company's stock, valued at $1,622,904. This trade represents a 13.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,092 shares of company stock valued at $471,609 in the last quarter. 54.57% of the stock is currently owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Essex Investment Management Co. LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 0.4% during the third quarter. Essex Investment Management Co. LLC now owns 200,516 shares of the company's stock valued at $5,011,000 after buying an additional 717 shares during the last quarter. Franklin Resources Inc. lifted its position in Kiniksa Pharmaceuticals by 1.7% in the 3rd quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock valued at $1,798,000 after acquiring an additional 1,100 shares in the last quarter. CWM LLC boosted its stake in Kiniksa Pharmaceuticals by 443.0% during the 3rd quarter. CWM LLC now owns 2,449 shares of the company's stock valued at $61,000 after purchasing an additional 1,998 shares during the last quarter. Quarry LP bought a new stake in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $50,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Kiniksa Pharmaceuticals by 2.3% in the second quarter. Bank of New York Mellon Corp now owns 115,143 shares of the company's stock worth $2,150,000 after purchasing an additional 2,563 shares during the last quarter. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.